Amneal Pharmaceuticals Added to S&P SmallCap 600® Index

Group 1 - Amneal Pharmaceuticals, Inc. has been added to the S&P SmallCap 600 Index, effective prior to the opening of trading on January 30, 2026 [1] - The S&P SmallCap 600 Index is a widely followed benchmark for U.S. small-cap equities, used by active managers and investors seeking exposure to companies with disciplined criteria for market capitalization, liquidity, sector representation, and sustained profitability [2] - The inclusion of Amneal in the index reflects its consistent operating and financial performance, placing it among a select group of pharmaceutical and biotechnology companies [2] Group 2 - The recognition of being included in the S&P SmallCap 600 Index is expected to enhance Amneal's visibility within the investment community and support the expansion of its investor base over time [3] - Inclusion in the index is typically associated with increased trading liquidity and broader investor awareness for companies in the U.S. small-cap universe [3] - Amneal Pharmaceuticals is a global biopharmaceutical company that develops, manufactures, and distributes over 290 pharmaceuticals, primarily in the United States, with a focus on complex product categories and therapeutic areas [4]